AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 180393
Drug: Weekly 5‐fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly 5‐fluorouracil, intravenously + placebo
Trial: 31934946
Drug: Transdermal 17β‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17β‐estradiol (n=30)
Trial: 31934946
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (n=29)
Trial: 31934946
Drug: Placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills and patch (n=36)
Trial: 26694694
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance training (twice weekly for six months)
Trial: 25263601
Drug: Ultrasound-guided injection
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided injection of botulinum toxin type A
Trial: 25263601
Drug: Manual needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual needle placement injection of botulinum toxin type A
Trial: 17092978
Drug: Diphenhydramine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (75 mg)
Trial: 15158296
Drug: Placebo (maltodextrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrine plus aspartame 15 g/day)
Trial: 11642081
Drug: lipantil therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lipantil therapy for 3 months
Trial: 8973788
Drug: Manidipine 10
RxNorm normalized name: manidipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manidipine 10 mg
Trial: 2192972
Drug: MK-927 (2%);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-927 (2%); single drop administered
Trial: 2192972
Drug: Pilocarpine (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine (1% q.d.); single dose administered
Trial: 2192972
Drug: MK-927 (2%);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-927 (2%); single dose administered
Trial: 2192972
Drug: Pilocarpine (1%);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine (1%); single dose administered
Trial: 856702
Drug: Dequalinium chloride
RxNorm normalized name: dequalinium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dequalinium chloride lozenges
Trial: 856702
Drug: Void lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Void lozenges (Control)
Trial: 31884945
Drug: FamPALcare intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FamPALcare intervention (5-weekly sessions delivered by community-based nurses)
Trial: 28782187
Drug: B-Vitamin therapy
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-Vitamin therapy
Trial: 19169898
Drug: Netilmicin with
RxNorm normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Netilmicin with parenteral nutrition
Trial: 19169898
Drug: Netilmicin with
RxNorm normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Netilmicin with fluid therapy
Trial: 17824470
Drug: Isapgol (5.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isapgol (5.6 g twice daily) + Atorvastatin (10 mg once daily)
Trial: 18991624
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg once daily)
Trial: 17824470
Drug: Isapgol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isapgol + Atorvastatin
Trial: 11477966
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (three doses at weekly intervals)
Trial: 11477966
Drug: Topical tetracycline
RxNorm normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracycline (daily over 6 weeks)
Trial: 1479050
Drug: Fluoxetine 5
RxNorm normalized name: fluoxetine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 5 mg/day
Trial: 24150249
Drug: Active tDCS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tDCS + Sertraline
Trial: 24150249
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS + Sertraline
Trial: 9881885
Drug: L. casei
RxNorm normalized name: L. casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. casei Shirota-fermented milk (100 ml three times daily for 4 weeks)
Trial: 9881885
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (unfermented milk, 100 ml three times daily for 4 weeks)
Trial: 9881885
Drug: L. casei
RxNorm normalized name: L. casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. casei Shirota-fermented milk
Trial: 2507181
Drug: Nalbuphine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (200 micrograms.kg‐1 bolus + 50 micrograms.kg‐1.hr‐1 infusion)
Trial: 31771038
Drug: Arthroscopic microfracture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic microfracture technique in combination with autologous bone marrow stem cells transplantation
Trial: 26010884
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment strategy using FOLFIRI.3 and gemcitabine (Arm 2)
Trial: 19303015
Drug: Sulphasalazine (IKK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine (IKK inhibitor)
Trial: 19303015
Drug: Losartan (AT1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (AT1 antagonist)
Trial: 15243278
Drug: Once-weekly alendronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly alendronate (ALN) 70 mg
Trial: 11061584
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg/d for 2 weeks
Trial: 8287341
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with a bismuth compound, metronidazole and either amoxicillin or tetracycline
Trial: 8287341
Drug: Anti-H. pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-H. pylori therapy added to conventional ulcer treatment
Trial: 2457074
Drug: Hydromorphone 4
RxNorm normalized name: HYDROmorphone 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone 4 mg
Trial: 2457074
Drug: Butorphanol 0.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 0.375 mg
Trial: 2457074
Drug: Butorphanol 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 0.75 mg
Trial: 2457074
Drug: Butorphanol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 1.5 mg
Trial: 2457074
Drug: Butorphanol 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 3 mg
Trial: 2457074
Drug: Butorphanol 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 6 mg
Trial: 28536999
Drug: OBV/PTV/r +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBV/PTV/r + RBV for 16 weeks (treatment-experienced)
Trial: 28536999
Drug: OBV/PTV/r +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBV/PTV/r + RBV for 16 weeks (treatment-experienced, relapsed after interferon therapy)
Trial: 21724265
Drug: Sertraline (50mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50mg/day p.o.)
Trial: 12019663
Drug: Paroxetine (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20-40 mg daily)
Trial: 11128665
Drug: Amitriptyline (75-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (75-150 mg daily)
Trial: 2869745
Drug: N-propylnorapomorphine (19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-propylnorapomorphine (19 mg oral dose)
Trial: 2869745
Drug: N-propylnorapomorphine (subchronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-propylnorapomorphine (subchronic dosage schedule)
Trial: 31805549
Drug: Topical Dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Dorzolamide for one week
Trial: 29858000
Drug: GP MDI
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP MDI 28.8 μg
Trial: 29606861
Drug: GP MDI
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP MDI 14.4 μg
Trial: 29858000
Drug: GP MDI
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP MDI 7.2 μg
Trial: 29858000
Drug: GP MDI
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP MDI 3.6 μg
Trial: 29858000
Drug: GP MDI
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP MDI 1.9 μg
Trial: 29858000
Drug: SAL DPI
RxNorm normalized name: salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAL DPI 50 μg
Trial: 21234625
Drug: Targeted school-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted school-based drama group therapy (DGT)
Trial: 12594112
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment (group 1)
Trial: 12594112
Drug: Simulated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated treatment (group 2)
Trial: 9028062
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with antituberculous drugs and corticosteroids
Trial: 6293264
Drug: Cyclic treatment
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic treatment with chlorambucil, methotrexate and 5‐fluorouracil
Trial: 27650094
Drug: Heyan Kuntai
RxNorm normalized name: niacinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heyan Kuntai Capsule (HYKT)
Trial: 27345931
Drug: Inhaled levodopa
RxNorm normalized name: levodopa Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled levodopa formulation (CVT-301)
Trial: 24995515
Drug: Albinterferon (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albinterferon (various doses/regimens)
Trial: 23523026
Drug: Ultrasound-assisted extraction
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-assisted extraction of phenolic compounds using 1g plant sample with 12 mL of 35% ethanol for 40 min.
Trial: 23523026
Drug: Ultrasound-assisted extraction
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-assisted extraction of phenolic compounds
Trial: 21078951
Drug: BMS‐488043 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐488043 800 mg
Trial: 21078951
Drug: BMS‐488043 1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐488043 1,800 mg
Trial: 19588284
Drug: Lidocaine spray
RxNorm normalized name: lidocaine Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine spray (S)
Trial: 16723058
Drug: Nicorandil 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil 0.1 mg kg‐1 (Group N)
Trial: 9459045
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg enteric-coated tablet taken under fasting conditions
Trial: 9459045
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg enteric-coated tablet taken before breakfast
Trial: 9459045
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg enteric-coated tablet taken after breakfast
Trial: 7932957
Drug: Biological valves
RxNorm normalized name: AmproMed for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological valves
Trial: 29650371
Drug: Turo group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turo group (8-week Turo training program, 60-minute sessions twice a week)
Trial: 29650371
Drug: Waiting-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list control group (no additional treatment during the same period)
Trial: 26244978
Drug: Selective Cytopheretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective Cytopheretic Device (SCD) therapy
Trial: 26244978
Drug: Continuous renal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous renal replacement therapy (CRRT) alone
Trial: 10819810
Drug: Nonoxynol 9
RxNorm normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoxynol 9 suppository (150 mg, intravaginally for 3 consecutive nights)
Trial: 10819810
Drug: Metronidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (2 g, single oral dose)
Trial: 6090368
Drug: Misonidazole (2.1-2.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misonidazole (2.1-2.7 g/m2 per treatment day, given 4 hours before irradiation)
Trial: 25688059
Drug: CT plus
RxNorm normalized name: Protect Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT plus Bev (7.5 mg/kg)
Trial: 19236580
Drug: Duodenal acid
RxNorm normalized name: Sus scrofa duodenum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duodenal acid perfusion (0.2 N, 5 mL min(‐1))
Trial: 8610912
Drug: succinylcholine 1
RxNorm normalized name: Succinylcholine 124 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: succinylcholine 1 mg/kg
Trial: 29508689
Drug: ANPEP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANPEP treatment
Trial: 26663152
Drug: Aleglitazar (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aleglitazar (150 µg once daily)
Trial: 19092244
Drug: Crofelemer 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crofelemer 500 mg
Trial: 19092244
Drug: Crofelemer 125
RxNorm normalized name: crofelemer 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crofelemer 125 mg
Trial: 19092244
Drug: Crofelemer 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crofelemer 250 mg
Trial: 16145414
Drug: Doxazosin controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin controlled release gastrointestinal therapeutic system formulation (4 mg once daily)
Trial: 16145414
Drug: Propiverine hydrochloride
RxNorm normalized name: propiverine hydrochloride
DrugBank: Propiverine (DB12278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine hydrochloride (20 mg once daily) plus doxazosin controlled release gastrointestinal therapeutic system formulation
Trial: 10418762
Drug: CGP 56697
RxNorm normalized name: Leucoflex CGP KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGP 56697 (4 x 4 tablets over 48 h)
Trial: 10418762
Drug: Halofantrine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine (3 x 2 tablets over 12 h with a second course 1 week later)
Trial: 7027988
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy package
Trial: 4074113
Drug: Insight-oriented therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insight-oriented therapy
Trial: 28234437
Drug: Active drugs
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drugs (mood stabilizer plus adjunctive antidepressant)
Trial: 24067460
Drug: S-based compound
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-based compound (NaSH)
Trial: 19478215
Drug: GFR 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFR 50 to 59 mL/min/1.73 m2
Trial: 19478215
Drug: GFR <50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFR <50 mL/min/1.73 m2
Trial: 12093952
Drug: Forced use
RxNorm normalized name: benzalkonium chloride Topical Solution [Clean Force]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forced use treatment (plaster cast on unimpaired arm for 1 month)
Trial: 28034987
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and specific neck exercises
Trial: 18436150
Drug: Brief psychosocial/behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief psychosocial/behavioral intervention plus antidepressant
Trial: 18436150
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care including antidepressants
Trial: 15151516
Drug: Montelukast (ML)
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast (ML) 10 mg
Trial: 7552181
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose inhaler
Trial: 31216321
Drug: modulated electro-hyperthermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modulated electro-hyperthermia (mEHT) administered 2/weekly immediately before external beam radiation
Trial: 22169051
Drug: SC golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SC golimumab 100 mg every 4 weeks through week 20 (n = 33)
Trial: 22169051
Drug: IV golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV golimumab 2 mg/kg at weeks 0 and 12 (n = 16)
Trial: 18175518
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol 2 mg daily
Trial: 18175518
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 0.05 mg daily
Trial: 10218748
Drug: COER-verapamil (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COER-verapamil (180 to 480 mg)
Trial: 10218748
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (30 to 120 mg/d)
Trial: 15251644
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin infusion therapy
Trial: 11704175
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (mean 3.8 sessions with obstetrician and one with midwife)
Trial: 11704175
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (mean 2.0 sessions)
Trial: 31999297
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of treatment with good visual acuity (CTGVA) group
Trial: 31999297
Drug: CTGVA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTGVA group (as-needed treatment)
Trial: 23743817
Drug: Light-emitting diodes
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light-emitting diodes therapy (LEDT)
Trial: 22539379
Drug: Hemocoagulase (2U
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemocoagulase (2U daily for 2 days postoperatively)
Trial: 17690713
Drug: Antigen-specific therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antigen-specific therapies
Trial: 12848782
Drug: Formoterol 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 9 micro g twice daily
Trial: 10568080
Drug: Greater impairment
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater impairment in instrumental activities of daily living
Trial: 9333106
Drug: Tolcapone 100
RxNorm normalized name: tolcapone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone 100 mg t.i.d.
Trial: 9333106
Drug: Tolcapone 200
RxNorm normalized name: tolcapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone 200 mg t.i.d.
Trial: 9333106
Drug: Tolcapone 400
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolcapone 400 mg t.i.d.
Trial: 9333106
Drug: Tolcapone 800
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolcapone 800 mg t.i.d.
Trial: 8739811
Drug: Levodopa/benserazide 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/benserazide 100/25 mg (given on days 2 and 7)
Trial: 1831059
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) 300 mg five times daily
Trial: 6642790
Drug: Cadralazine (CD)
RxNorm normalized name: cadralazine
DrugBank: Cadralazine (DB13452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadralazine (CD) 15 mg 1 X daily, increased to 20 mg 1 X daily if poor response
Trial: 6642790
Drug: Dihydralazine (HD)
RxNorm normalized name: dihydralazine
DrugBank: Dihydralazine (DB12945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydralazine (HD) 25 mg 3 X daily, increased to 50 mg 2 X daily if poor response